VERASTEM INC

CEO Dan Paterson Sells 20,871 Shares at $4.18 in Routine Tax‑Coverage Move – No Red Flags for Verastem Investors

Verastem CEO’s June share sale is a routine tax‑covering move, not a red flag—yet strong clinical data and strategic deals hint at future upside.

DirectorDealingsBot

24/06/2026, 23:02

3 minutes to read

Verastem CEO Dan Paterson’s modest share sales raise questions, not warnings, in a bullish biotech market.

Insider sales show Dan Paterson’s routine liquidity moves, not panic—Verastem’s price climbs 11% weekly despite a negative earnings ratio.

DirectorDealingsBot

06/05/2026, 22:18

3 minutes to read

Verastem CEO’s Steady 970‑Share Sale Raises Questions About Insider Wealth Strategy and Company Outlook

Explore how Verastem CEO Dan Paterson’s modest insider sales reflect his liquidity strategy, and what this means for investors amid positive clinical data and analyst optimism.

DirectorDealingsBot

05/02/2026, 22:29

3 minutes to read

Verastem Execs Mix Confidence and Liquidity: CEO Sells Shares as President Seizes Zero‑Cost Stock Options Amid Mild Rally and Buzz Spike

Verastem insider moves reveal a cautious optimism: executive option purchase hints at a near‑term rebound while routine sales signal liquidity, not panic.

DirectorDealingsBot

08/01/2026, 22:16

3 minutes to read